February 7, 2020

Mylan issued an alert regarding the manufacturing challenges in the production of EpiPen (epinephrine injection, USP) 0.3 mg and EpiPen Jr (epinephrine Injection, USP) 0.15 mg auto-injectors and the authorized generic versions of these strengths. These challenges resulted in the reduced availability of these product.

VDP temporarily removed the non-preferred status from the following:

NDC Name
00093598627 Epinephrine 0.3 mg auto-injector

This change will allow providers to prescribe these product NDCs without requiring non-preferred prior authorization and allow continued access to medication. The current preferred NDCs are:

NDC Name
00093598527 Epinephrine 0.15 mg auto-injector
00115169449 Epinephrine 0.3 mg auto-injector
00115169549 Epinephrine 0.15 mg auto-injector
49502010101 Epinephrine 0.15 Mg auto-injector
49502010102 Epinephrine 0.15 Mg auto-injector
49502010201 Epinephrine 0.3 Mg auto-injector
49502010202 Epinephrine 0.3 Mg auto-injector

This is a temporary change until the preferred products are sufficiently available again in the market. VDP confirmed there may be outages varying between pharmacies despite Mylan products no longer identified as a shortage according to FDA and ASHP. VDP will send out further announcements regarding future PDL status changes of these NDCs.

Resources:

Tags: 
Drug